<DOC>
	<DOCNO>NCT02501954</DOCNO>
	<brief_summary>To determine treatment cisplatin radiation follow carbo taxol reduces rate recurrence compare sandwich therapy .</brief_summary>
	<brief_title>Trial Cisplatin Plus Radiation Followed Carbo Taxol Vs . Sandwich Therapy Carbo Taxol Followed Radiation Then Further Carbo Taxol</brief_title>
	<detailed_description>To determine treatment cisplatin volume-directed radiation follow carboplatin paclitaxel 4 cycle ( experimental arm ) reduce rate recurrence ( increase recurrence-free survival ) compare sandwich therapy ( control arm ) . To determine treatment cisplatin volume-directed radiation follow carboplatin paclitaxel 4 cycle ( experimental arm ) reduce rate death ( increase survival ) compare sandwich therapy ( control arm ) . To compare regimen respect tolerability acute late adverse effect therapy .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Uterine Neoplasms</mesh_term>
	<mesh_term>Cystadenocarcinoma , Serous</mesh_term>
	<mesh_term>Adenocarcinoma , Clear Cell</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>All patient Surgical Stage III IVA endometrial carcinoma per FIGO 2009 stag criterion , include clear cell serous papillary undifferentiated carcinoma . Surgical Stage III disease include patient positive adnexa , parametrial involvement , tumor invade serosa , positive pelvic and/or paraaortic node , vaginal involvement . Surgical Stage IVA include patient bladder bowel mucosal involvement , spread outside pelvis . Patients FIGO 2009 surgical Stage I II endometrial clear cell serous carcinoma positive peritoneal cytology . Surgery must include hysterectomy bilateral salpingooophorectomy . Pelvic lymph node sample paraaortic lymph node sample optional . Patients GOG Performance Status 0 , 1 , 2 . Patients adequate organ function , reflect follow parameter : WBC ≥ 3000/mcl Absolute neutrophil count ( ANC ) ≥ 1500/mcl Platelet count ≥ 100,000/mcl SGOT , SGPT , alkaline phosphatase ≤ 2.5 X upper limit normal ( ULN ) Bilirubin ≤ 1.5 X ULN Creatinine ≤ institutional ULN Patients must 18 year age old . Entry study limit 8 week date surgery . Patients carcinosarcoma . Patients recurrent endometrial cancer . Patients residual tumor surgery ( single site ) exceed 1 cm maximum dimension . Patients pelvic abdominal radiation therapy . Patients positive pelvic washing extrauterine disease NOT eligible histology clear cell papillary serous carcinoma . Patients history invasive malignancy , exception nonmelanoma skin cancer , exclude evidence active malignancy within last five year . Patients also exclude previous cancer treatment contraindicate protocol therapy . Patients history serious comorbid illness uncontrolled illness would preclude protocol therapy . Patients estimate survival less three month . Patients FIGO 2009 Stage IVB endometrial cancer . Patients parenchymal liver metastasis . Patients receive prior chemotherapy endometrial cancer . Patients history myocardial infarction , unstable angina , uncontrolled arrhythmia within 3 month enrollment .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>